Clinical Trial Update: RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Cudetaxestat in idiopathic pulmonary fibrosis (IPF) evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Cudetaxestat

Snippet

Sponsor: Blade Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: UNKNOWN